Apply to trial NCT06768905

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening